Moreover, high TPX2 expression is significantly associated with shorter time to BCR as indicated by survival analysis of primary and metastatic PCa of the MSKCC dataset49 (Fig. 7c), implying its biological role for tumor progression and its potential as a biomarker and therapeutic target for advanced PCa. This evidence concerns the gene BCR and neoplasm.